Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenkang Injection is a Traditional Chinese Medicine (TCM) formulation widely used in China for the treatment of chronic kidney disease (CKD) and renal failure. It is composed of extracts from four medicinal herbs: *Rheum palmatum* (Rhubarb), *Astragalus membranaceus* (Mongolian Milkvetch), *Salvia miltiorrhiza* (Red Sage), and *Carthamus tinctorius* (Safflower). The injection is designed to improve renal function by promoting blood circulation, removing blood stasis, and clearing heat and toxins. Clinically, it is used to lower serum creatinine and blood urea nitrogen levels, reduce proteinuria, and delay the progression of renal insufficiency. It is often administered as an intravenous infusion and has been the subject of extensive post-marketing safety and efficacy monitoring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenkang Injection.